ArticleNaunyn-Schmiedeberg's archives of pharmacology2020
Pharmacological activities of 4-methylene-8-hydroxybisabola-2,10-diene-9-one, a new compound isolated from Ryudai gold (Curcuma longa).
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Anti-Inflammatory Effects of Bisacurone Isolated fromMolecules (Basel, Switzerland) · 2026Article
- Anti-Inflammatory, Wound Healing, and Anti-Diabetic Effects of Pure Active Compounds Present in the Ryudai Gold Variety ofMolecules (Basel, Switzerland) · 2024Article
- The Combined Treatment of Curcumin with Verapamil Ameliorates the Cardiovascular Pathology in a Williams-Beuren Syndrome Mouse Model.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported the antifungal, antioxidant, and vasodilator effects of Ryudai gold (RD) and isolated some potentially active compounds. Here, we aimed to identify other active compounds present in RD and investigate their pharmacological effects, in terms of antioxidant, and inhibitory activities against skin disease-related enzymes, pancreatic α-amylase, and lipase enzymes. The methanol extract of RD rhizomes was subjected to repeated fractionation by silica gel column, Toyopearl HW-40F column, and high-performance liquid chromatography to obtain a pure compound. The isolated compound was characterized by analyzing its spectroscopic data, particularly nuclear magnetic resonance spectra. Inhibitory activities against α-amylase, pancreatic lipase, elastase, collagenase, xanthine oxidase, and tyrosinase were evaluated to investigate its potential antidiabetic, antiobesity, and enzyme inhibitory effects. Antioxidant activity was evaluated using 2,2-diphenyl-1-picrylhydrazyl-scavenging, reducing power, and 2-deoxyribose degradation assays. The purified compound was recognized as 4-methylene-8-hydroxybisabola-2,10-diene-9-one, a new compound. The content of this compound was 0.068 μmol/g or 0.016 mg/g of dry RG powder. Our results suggested that 4-methylene-8-hydroxybisabola-2,10-diene-9-one exhibited antidiabetic, antiobesity, enzyme inhibitory, and antioxidant activities by inhibiting their respective enzymes activity. 4-methylene-8-hydroxybisabola-2,10-diene-9-one could be a promising candidate therapeutic agent or a lead compound for the development of new synthetic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.